KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 Page 1

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that it presented additional analyses of the efficacy and safety of sebetralstat from double-blind, placebo-controlled, crossover Phase 2 and Phase 3 clinical studies, as well as interim data from KONFIDENT-S, an open-label extension Phase 3 study, and real-world patient data at the Bradykinin Symposium 2024 taking place September 5-6 in Berlin, Germany. Sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adult and pediatric patients 12 years of age and older.

“Delays or refusals in the treatment of HAE attacks are often related to the administration of currently approved on-demand injectable treatments that often result in injection site reactions or pain. The data presented today highlight that oral sebetralstat may overcome these challenges and has a safety profile no different from placebo,” said Emel Aygören-Pürsün, MD, a specialist in internal medicine in the Department of Oncology, Hematology and Hemostaseology at the Department of Children and Adolescents at the University Hospital Frankfurt, and a lead investigator for the Phase 2, Phase 3 KONFIDENT and KONFIDENT-S trials. “Sebetralstat also resulted in rapid symptom relief in the clinical trials. If approved, sebetralstat could represent a major advance for people living with HAE by addressing critical gaps in the current standard of care for on-demand treatment of attacks.”